Investor Relations > details

Zensun Achieved Important Progress in Australian Phase II clinical Trial


After two years’ clinical study in Australia, Zensun’s rhNRG-1 has achieved important progress in Phase II a clinical trial

The clinical study in Australian has three paralleled dosage groups. The results demonstrated  that all these dosage groups could improve heart function. T test showed the P value was 0.0046 after acute administration; One month after administration, the P value became 0.0237. It means that with rhNRG-1 therapy, the heart function has significant improvement. It also showed that heart function improvement has a linear relationship with dosage.

Now, Zensun are committed to commerce Phase IIb clinical study in China and application of US new drug clinical study. The new progress of Australian Phase II clinical study can provide important evidence for US clinical study.